~~<i id='BE39C1AF9B'><strike id='BE39C1AF9B'><tt id='BE39C1AF9B'><pre id='BE39C1AF9B'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：knowledge 2025-09-29 07:58:50 Page View：3

Lessons Learned is STAT Plus’ weekly column on careers in biomedicine. If you’re thinking of jumping from academics to industry/business or vice versa, join us each week for useful tips. And if you’ve recently jumped, send us a note: kate.she[email protected]. Your experience might make a future column.

Who we talked to:

Lily Ting, 35. Associate, PureTech Health, Boston. Head of R&D, Commense, Boston. Expert, protein-protein interactions. Expert, human-human interactions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

knowledge

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Biotech lab space demand falls sharply

AdobeDemandfornewlabspacehasplummetedbymorethanhalfsincetheendof2021,andlifesciencevacancyratesareth

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

How Vertex's cystic fibrosis drug is changing patients' lives

SusanUlan,right,greetshergranddaughterIvy,andherdaughterJessieAnderson,atAnderson'shome.SuzanneKreit